WHO ICTRP trial
The effect of haemostatic factor,Octafibrin in congenital afibrinogenemia
IRCT2014112320051N3 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT2014112320051N3 |
|---|---|
| Public title | The effect of haemostatic factor,Octafibrin in congenital afibrinogenemia |
| Scientific title | Prospective,open-label,uncontrolled,phase III study to assess the efficacy, safety and pharmacokinetics of Octafibrin for on-demand treatment of acute bleeding and to prevent bleeding during and after surgery in paediatric subjects with congenital fibrinogen deficiency |
| Primary sponsor | Octapharma |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Congenital Afibrinogenemia. Hereditary deficiency of other clotting factors;?D68.2;Hereditary deficiency of other clotting factors |
| Interventions | Infusion of Octafibrin.;Treatment - Drugs;Infusion of Octafibrin |
| Registration date | Sep 1, 2015 |
| Target size | 3 |
| Secondary IDs | 2014-005115-16 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: